# Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic

Source: https://onco.cc/trials/nct06662006/  
OnCo record `nct06662006` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, now recruiting.

## Summary

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT06662006 by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, with a registry enrolment figure of 56 participants, started 2024-03-01 and due to reach its primary completion in 2027-12. Interventions recorded: nal-IRI,5-fu,LV, benmelstobart, anlotinib. Conditions listed: Advanced Metastatic Pancreatic Cancer. Primary outcome: Objective effective rate (ORR). Pancreatic eligibility wording from the registry: "Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06662006
- Phase: 2
- Setting: Efficacy and Safety of Second-line Therapy by Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT in Metastatic Pancreatic Cancer Patients: a Prospective, Multicentre, Single-arm, Multi-cohort Study
- Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Enrolled: 56

## Sources

- ClinicalTrials.gov NCT06662006: https://clinicaltrials.gov/study/NCT06662006

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06662006.json